Education
About Us
Working with TipRanks
Follow Us
Arovella Therapeutics Limited (AU:ALA)
ASX:ALA
RESEARCH TOOLSreports
Total Valuation
Arovella Therapeutics Limited has a market cap or net worth of AU$98.26M. The enterprise value is AU$30.40M.
Market CapAU$98.26M
Enterprise ValueAU$30.40M
Share Statistics
Arovella Therapeutics Limited has 1,183,870,600 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,183,870,600
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Arovella Therapeutics Limited’s return on equity (ROE) is -0.78 and return on invested capital (ROIC) is -96.15%.
Return on Equity (ROE)-0.78
Return on Assets (ROA)-0.66
Return on Invested Capital (ROIC)-96.15%
Return on Capital Employed (ROCE)-0.96
Revenue Per Employee―
Profits Per Employee―
Employee Count―
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Arovella Therapeutics Limited is -15.61. Arovella Therapeutics Limited’s PEG ratio is 0.39.
PE Ratio-15.61
PS Ratio0.00
PB Ratio9.41
Price to Fair Value12.16
Price to FCF-5.56
Price to Operating Cash Flow-5.56
PEG Ratio0.39
Income Statement
In the last 12 months, Arovella Therapeutics Limited had revenue of 17.00K and earned -8.75M in profits. Earnings per share was -0.01.
Revenue17.00K
Gross Profit17.00K
Operating Income-10.81M
Pretax Income-8.75M
Net Income-8.75M
EBITDA-8.83M
Earnings Per Share (EPS)-0.01
Cash Flow
In the last 12 months, operating cash flow was -6.09M and capital expenditures -453.80K, giving a free cash flow of -6.54M billion.
Operating Cash Flow-6.09M
Free Cash Flow-6.54M
Free Cash Flow per Share>-0.01
Dividends & Yields
Arovella Therapeutics Limited pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.33
52-Week Price Change-42.86%
50-Day Moving Average0.08
200-Day Moving Average0.14
Relative Strength Index (RSI)47.94
Average Volume (3m)1.70M
Important Dates
Arovella Therapeutics Limited upcoming earnings date is Aug 27, 2025, TBA Not Confirmed.
Last Earnings DateFeb 26, 2025
Next Earnings DateAug 27, 2025
Ex-Dividend Date―
Financial Position
Arovella Therapeutics Limited as a current ratio of 6.45, with Debt / Equity ratio of 0.00%
Current Ratio6.45
Quick Ratio6.45
Debt to Market Cap0.00
Net Debt to EBITDA1.44
Interest Coverage Ratio-1.25K
Taxes
In the past 12 months, Arovella Therapeutics Limited has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Arovella Therapeutics Limited EV to EBITDA ratio is -14.01, with an EV/FCF ratio of -17.58.
EV to Sales7.28K
EV to EBITDA-14.01
EV to Free Cash Flow-17.58
EV to Operating Cash Flow-17.90
Balance Sheet
Arovella Therapeutics Limited has AU$11.75M in cash and marketable securities with AU$0.00 in debt, giving a net cash position of -AU$11.75M billion.
Cash & Marketable SecuritiesAU$11.75M
Total DebtAU$0.00
Net Cash-AU$11.75M
Net Cash Per Share>-AU$0.01
Tangible Book Value Per ShareAU$0.01
Margins
Gross margin is -739.07%, with operating margin of -63595.65%, and net profit margin of -51447.26%.
Gross Margin-739.07%
Operating Margin-63595.65%
Pretax Margin-51447.26%
Net Profit Margin-51447.26%
EBITDA Margin-51959.76%
EBIT Margin-51396.49%
Analyst Forecast
The average price target for Arovella Therapeutics Limited is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast315.11%
EPS Growth Forecast51.16%